Original Research Article
Metabolic Syndrome and Dementia Risk in a Multiethnic Elderly CohortMuller M.a, i · Tang M.-X.a, b · Schupf N.c-e, h · Manly J.J.a, c, f · Mayeux R.a, c-f · Luchsinger J.A.a, c, d, g
aGertrude H. Sergievsky Center, bDivision of Biostatistics, Joseph P. Mailman School of Public Health, cTaub Institute for Research of Alzheimer’s Disease and the Aging Brain, and dDepartment of Epidemiology, Joseph P. Mailman School of Public Health, Columbia University, eDepartment of Psychiatry, fDepartment of Neurology, and gDivision of General Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, N.Y., and hLaboratory of Epidemiology, NYS Institute for Basic Research in Developmental Disabilities, Staten Island, N.Y., USA; iDepartment of Geriatric Medicine, University Medical Center, Utrecht, The Netherlands
José A. Luchsinger
Division of General Medicine
PH9East-105, 630 West 168th Street
New York, NY 10032 (USA)
Tel. +1 212 305 4730, Fax +1 212 305 9349, E-Mail email@example.com
Do you have an account?
Background/Aims: The metabolic syndrome (MeSy) may be related to Alzheimer’s disease (AD). Our aims were to investigate the association of the MeSy with incident dementia in a multiethnic elderly cohort in the United States. Methods: We conducted cross-sectional and prospective analyses in 2,476 men and women aged 65 years and older and with data available on the MeSy and dementia diagnosis in Northern New York City. MeSy was defined by the National Cholesterol Education Program Adult Treatment Program III and the European Group for the Study of Insulin Resistance criteria. Dementia was diagnosed using standard criteria. Results: No association was found between MeSy and prevalent dementia. After 4.4 years of follow-up, 236 individuals of the 1,833 without prevalent dementia developed dementia. MeSy was not associated with incident dementia. Of the components of the MeSy, diabetes and hyperinsulinemia were associated with an increased risk of incident AD [hazard ratio 1.4 (95% CI 1.0–2.1), and hazard ratio 1.4 (95% CI 0.9–2.7), respectively] and dementia associated with stroke [hazard ratio 1.9 (95% CI 1.1–3.1), and hazard ratio 2.3 (95% CI 1.1–4.7), respectively]. Conclusions: The MeSy was not associated with an increased dementia risk in a multiethnic elderly cohort, but diabetes and hyperinsulinemia were. In the elderly, examining diabetes and hyperinsulinemia separately may be preferable to using the MeSy as a risk factor.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.